Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.

Umesh Gangishetti,J Christina Howell,Richard J Perrin,Natalia Louneva,Kelly D Watts,Alexander Kollhoff,Murray Grossman,David A Wolk,Leslie M Shaw,John C Morris,John Q Trojanowski,Anne M Fagan,Steven E Arnold,William T Hu

Alzheimer's research & therapy（2018）

引用 24|浏览26

暂无评分

摘要

CSF proteins associated with AD clinical stages and progression can complement Aβ and tau markers to inform neurodegeneration. A validated panel inclusive of multiple biomarker features (etiology, stage, progression) can improve AD phenotyping along the A/T/N framework.

查看译文

关键词

Biomarkers,Fatty acid binding protein,Interleukin-10,Mild cognitive impairment,Neurofilament light chain

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要